HUE042919T2 - Genetikai immunizáció sejthez kapcsolódó antigének - például P2X7, CXCR7 vagy CXCR4 - elleni immunglobulinok elõállítására - Google Patents
Genetikai immunizáció sejthez kapcsolódó antigének - például P2X7, CXCR7 vagy CXCR4 - elleni immunglobulinok elõállításáraInfo
- Publication number
- HUE042919T2 HUE042919T2 HUE09799348A HUE09799348A HUE042919T2 HU E042919 T2 HUE042919 T2 HU E042919T2 HU E09799348 A HUE09799348 A HU E09799348A HU E09799348 A HUE09799348 A HU E09799348A HU E042919 T2 HUE042919 T2 HU E042919T2
- Authority
- HU
- Hungary
- Prior art keywords
- cxcr7
- cxcr4
- associated antigens
- against cell
- genetic immunization
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20318808P | 2008-12-19 | 2008-12-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE042919T2 true HUE042919T2 (hu) | 2019-07-29 |
Family
ID=42269156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE09799348A HUE042919T2 (hu) | 2008-12-19 | 2009-12-21 | Genetikai immunizáció sejthez kapcsolódó antigének - például P2X7, CXCR7 vagy CXCR4 - elleni immunglobulinok elõállítására |
Country Status (11)
Country | Link |
---|---|
US (2) | US9260508B2 (hu) |
EP (2) | EP3470425A3 (hu) |
JP (2) | JP2012512646A (hu) |
CN (2) | CN102257003B (hu) |
AU (2) | AU2009329501B2 (hu) |
CA (1) | CA2747644C (hu) |
CY (1) | CY1122131T1 (hu) |
DK (1) | DK2370465T3 (hu) |
ES (1) | ES2729320T3 (hu) |
HU (1) | HUE042919T2 (hu) |
WO (1) | WO2010070145A2 (hu) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9512236B2 (en) | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
EP2285833B1 (en) | 2008-05-16 | 2014-12-17 | Ablynx N.V. | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
CN102257003B (zh) | 2008-12-19 | 2017-04-05 | 埃博灵克斯股份有限公司 | 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫 |
WO2011083141A2 (en) * | 2010-01-08 | 2011-07-14 | Ablynx Nv | Method for generation of immunoglobulin sequences by using lipoprotein particles |
US8937164B2 (en) | 2010-03-26 | 2015-01-20 | Ablynx N.V. | Biological materials related to CXCR7 |
JP5933573B2 (ja) * | 2010-11-08 | 2016-06-15 | ノバルティス アーゲー | Cxcr2結合ポリペプチド |
US9765148B2 (en) * | 2011-03-16 | 2017-09-19 | Argen-X N.V. | Antibodies to CD70 |
US20150158948A9 (en) * | 2011-03-28 | 2015-06-11 | Francis Descamps | Bispecific anti-cxcr7 immunoglobulin single variable domains |
AU2012316859A1 (en) | 2011-09-29 | 2014-04-17 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
WO2013105856A1 (en) | 2012-01-13 | 2013-07-18 | Apo-T B.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
WO2013178783A1 (en) | 2012-06-01 | 2013-12-05 | Ablynx N.V. | P2x7 receptor antagonists and agonists |
AU2013281327A1 (en) * | 2012-06-26 | 2015-01-22 | Apo-T B.V. | Binding molecules targeting pathogens |
PT2951201T (pt) | 2013-01-30 | 2018-01-09 | Univ Brussel Vrije | Novos polipéptidos quiméricos para rastreamento e fins de descoberta de fármacos |
AU2014214054B2 (en) | 2013-02-05 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Muscarinic acetylcholine receptor binding agents and uses thereof |
GB2517953A (en) * | 2013-09-05 | 2015-03-11 | Argen X Bv | Antibodies to complex targets |
JP6687525B2 (ja) | 2014-01-30 | 2020-04-22 | ブイアイビー ブイゼットダブリュVib Vzw | オピオイド受容体結合剤およびその使用 |
CA2955554C (en) | 2014-07-22 | 2022-07-05 | Vib Vzw | Methods to select for agents that stabilize protein complexes |
CN104479016A (zh) * | 2014-12-31 | 2015-04-01 | 广州吉赛生物科技有限公司 | 利用dna纹身免疫制备抗体的方法 |
EP3374395A1 (en) * | 2015-11-12 | 2018-09-19 | Ablynx NV | Improved p2x7 receptor binders and polypeptides comprising the same |
EP3833387A4 (en) * | 2018-08-27 | 2022-05-11 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRUS INFECTION |
US11312754B2 (en) * | 2019-05-31 | 2022-04-26 | Access Business Group International Llc | Sunflower seed protein-derived peptides |
JPWO2021006212A1 (hu) * | 2019-07-08 | 2021-01-14 | ||
WO2021140205A1 (en) | 2020-01-10 | 2021-07-15 | Confo Therapeutics N.V. | Methods for generating antibodies and antibody fragments and libraries comprising same |
US20220356468A1 (en) * | 2021-05-03 | 2022-11-10 | Twist Bioscience Corporation | Variant nucleic acid libraries for ion channels |
EP4334515A1 (en) * | 2021-05-03 | 2024-03-13 | Twist Bioscience Corporation | Variant nucleic acid libraries for glycans |
CN117003876B (zh) * | 2023-08-31 | 2024-06-18 | 恺佧生物科技(上海)有限公司 | 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
DK1087013T3 (da) | 1992-08-21 | 2009-05-11 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
AU694745B2 (en) | 1993-09-10 | 1998-07-30 | Trustees Of Columbia University In The City Of New York, The | Uses of green fluorescent protein |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
AU4964896A (en) | 1995-01-19 | 1996-08-07 | Research Foundation Of The State University Of New York, The | Genes encoding an insect calcium channel |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US5693492A (en) | 1995-05-05 | 1997-12-02 | Merck & Co., Inc. | DNA encoding glutamate gated chloride channels |
DK0851874T3 (da) | 1995-09-22 | 2000-03-06 | Bioimage A S | Hidtil ukendte varianter af grønt fluorescerende protein, GFP |
US6027881A (en) | 1996-05-08 | 2000-02-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence |
US6124128A (en) | 1996-08-16 | 2000-09-26 | The Regents Of The University Of California | Long wavelength engineered fluorescent proteins |
WO1998021355A1 (en) | 1996-11-15 | 1998-05-22 | Life Technologies, Inc. | Mutants of green fluorescent protein |
WO1999023221A2 (en) | 1997-10-27 | 1999-05-14 | Unilever Plc | Multivalent antigen-binding proteins |
BR9907241A (pt) | 1998-01-26 | 2000-10-17 | Unilever Nv | Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
WO2000043507A1 (en) | 1999-01-19 | 2000-07-27 | Unilever Plc | Method for producing antibody fragments |
AUPP991199A0 (en) * | 1999-04-21 | 1999-05-13 | University Of Sydney, The | Methods for diagnosing pre-cancerous and cancerous conditions |
GB9922124D0 (en) | 1999-09-17 | 1999-11-17 | Pfizer Ltd | Phosphodiesterase enzymes |
US7608681B2 (en) | 1999-12-24 | 2009-10-27 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
WO2001090190A2 (en) | 2000-05-26 | 2001-11-29 | National Research Council Of Canada | Single-domain antigen-binding antibody fragments derived from llama antibodies |
CA2441903C (en) | 2000-05-26 | 2012-07-31 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
CA2434490C (en) * | 2001-01-17 | 2014-06-03 | Intreat Pty Limited | Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions |
AU2002335930B2 (en) | 2001-03-09 | 2005-07-28 | Morphosys Ag | Serum albumin binding moieties |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
EP1433793A4 (en) | 2001-09-13 | 2006-01-25 | Inst Antibodies Co Ltd | METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
WO2003050531A2 (en) * | 2001-12-11 | 2003-06-19 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
EP1456237A2 (en) | 2001-12-21 | 2004-09-15 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Method for cloning of variable domain sequences |
CA2471645A1 (en) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Immunoconjugates useful for treatment of tumours |
AU2003285578B2 (en) | 2002-12-03 | 2010-07-15 | Ucb Pharma S.A. | Assay for identifying antibody producing cells |
GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
KR101025143B1 (ko) | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | 가수분해상으로 안정한 말레이미드-종결 중합체 |
EP1615991A4 (en) * | 2003-04-03 | 2007-12-19 | Bristol Myers Squibb Co | POLYNUCLEOTIDE ENCODING A NEW HUMAN P2X7 SPLICE VARIANT CALLED HBMYP2X7V |
GB0312321D0 (en) * | 2003-05-29 | 2003-07-02 | Astrazeneca Ab | New combination |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
ES2385829T3 (es) | 2003-08-20 | 2012-08-01 | Ucb Pharma, S.A. | Métodos para obtener anticuerpos |
ATE485307T1 (de) | 2003-11-07 | 2010-11-15 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
US20060008601A1 (en) | 2004-06-25 | 2006-01-12 | Zeik Douglas B | Flexible laminate having an integrated pressure release valve |
KR101151957B1 (ko) | 2004-07-22 | 2012-06-01 | 로저 킹돈 크레이그 | 결합 분자 |
US20080107601A1 (en) | 2004-10-13 | 2008-05-08 | Ablynx N.V. | Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease |
WO2006040154A2 (en) | 2004-10-14 | 2006-04-20 | Dublin City University | Prokaryotic two hybrid system |
CA2595682A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
EP1934259A2 (en) | 2005-10-11 | 2008-06-25 | Ablynx N.V. | Nanobodies and polypeptides against egfr and igf-ir |
WO2008000279A1 (en) | 2006-06-26 | 2008-01-03 | Aida Centre, S.L. | Blister package integrating rfid based tags |
AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
EP2082032A4 (en) * | 2006-10-10 | 2010-06-30 | Biosceptre Int Ltd | ANTIBODIES AGAINST NON-FUNCTIONAL P2X7 RECEPTOR PRODUCING HYBRIDOMES |
WO2008074839A2 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
US20110189203A1 (en) | 2007-11-27 | 2011-08-04 | Ablynx N.V. | Immunoglobulin constructs |
JP2011516603A (ja) | 2008-04-17 | 2011-05-26 | アブリンクス エン.ヴェー. | 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド |
EP2285833B1 (en) * | 2008-05-16 | 2014-12-17 | Ablynx N.V. | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
CN102257003B (zh) | 2008-12-19 | 2017-04-05 | 埃博灵克斯股份有限公司 | 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫 |
WO2013178783A1 (en) * | 2012-06-01 | 2013-12-05 | Ablynx N.V. | P2x7 receptor antagonists and agonists |
-
2009
- 2009-12-21 CN CN200980151192.3A patent/CN102257003B/zh active Active
- 2009-12-21 EP EP18207001.1A patent/EP3470425A3/en not_active Withdrawn
- 2009-12-21 AU AU2009329501A patent/AU2009329501B2/en active Active
- 2009-12-21 EP EP09799348.9A patent/EP2370465B1/en active Active
- 2009-12-21 ES ES09799348T patent/ES2729320T3/es active Active
- 2009-12-21 HU HUE09799348A patent/HUE042919T2/hu unknown
- 2009-12-21 CA CA2747644A patent/CA2747644C/en active Active
- 2009-12-21 CN CN201710127717.6A patent/CN107011434B/zh active Active
- 2009-12-21 DK DK09799348.9T patent/DK2370465T3/da active
- 2009-12-21 WO PCT/EP2009/067687 patent/WO2010070145A2/en active Application Filing
- 2009-12-21 US US12/643,286 patent/US9260508B2/en active Active
- 2009-12-21 JP JP2011541503A patent/JP2012512646A/ja active Pending
-
2015
- 2015-04-02 JP JP2015076148A patent/JP6034435B2/ja active Active
-
2016
- 2016-01-11 AU AU2016200146A patent/AU2016200146B9/en active Active
- 2016-02-10 US US15/040,323 patent/US10023633B2/en active Active
-
2019
- 2019-04-22 CY CY20191100439T patent/CY1122131T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2747644A1 (en) | 2010-06-24 |
CN107011434A (zh) | 2017-08-04 |
EP3470425A3 (en) | 2019-07-17 |
WO2010070145A2 (en) | 2010-06-24 |
US9260508B2 (en) | 2016-02-16 |
JP6034435B2 (ja) | 2016-11-30 |
CN102257003B (zh) | 2017-04-05 |
AU2009329501A1 (en) | 2010-06-24 |
EP2370465A2 (en) | 2011-10-05 |
AU2016200146A1 (en) | 2016-02-04 |
JP2012512646A (ja) | 2012-06-07 |
DK2370465T3 (da) | 2019-05-06 |
JP2015155429A (ja) | 2015-08-27 |
CA2747644C (en) | 2023-01-24 |
AU2016200146B2 (en) | 2018-02-01 |
CN107011434B (zh) | 2021-02-19 |
EP3470425A2 (en) | 2019-04-17 |
US20100173799A1 (en) | 2010-07-08 |
CY1122131T1 (el) | 2020-11-25 |
WO2010070145A3 (en) | 2010-12-02 |
ES2729320T3 (es) | 2019-10-31 |
US10023633B2 (en) | 2018-07-17 |
CN102257003A (zh) | 2011-11-23 |
AU2016200146B9 (en) | 2018-02-15 |
US20160264664A1 (en) | 2016-09-15 |
AU2009329501B2 (en) | 2015-11-26 |
EP2370465B1 (en) | 2019-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUE042919T2 (hu) | Genetikai immunizáció sejthez kapcsolódó antigének - például P2X7, CXCR7 vagy CXCR4 - elleni immunglobulinok elõállítására | |
HK1223382A1 (zh) | 免疫療法的新型免疫抗原表位 | |
IL229512A0 (en) | Anti-vegf antibodies | |
AP2011005719A0 (en) | Anti-IGF antibodies. | |
IL212066A (en) | 4cxcr antibodies, preparations containing them, processes for their production and selection and use for cancer treatment | |
PL2152290T3 (pl) | Sposoby podawania przeciwciał przeciw IL-5 | |
MY178926A (en) | Bispecific anti-vegf/anti-ang-2 antibodies | |
IL222116A (en) | Two-valent, bi-specific antibody against 2-ang / vegf | |
IL217827A0 (en) | Muc1 antibodies, nucleic acids encoding the same and methods for producing the same | |
EP2349331A4 (en) | HUMANIZED ANTIBODIES TO IL-6 | |
WO2011110642A3 (en) | Monoclonal antibodies against c-met | |
IL207217A0 (en) | Humanized anti-c5ar antibodies | |
IL206715A (en) | Anti-mif anti-mif antibodies, medicinal preparations containing them, their use and methods for their preparation | |
IL211010A (en) | Antibody, antibody hybridoma, antibody-containing conjugate, antibody-containing drug and / or conjugate and their uses | |
SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
IL219801A (en) | Anti-a4 antibody. 4c isolates, vectors encoded by them, methods of preparation, preparations containing them and their use | |
IL205073A (en) | 2 bst antibodies, methods of making them, medicinal preparations containing them and their use | |
EP2217626A4 (en) | EPITOP FOR NEUTRALIZING ANTIBODIES | |
EP2485752A4 (en) | FUSION - PROTEIN VACCINES. ENTEROXROGENIC COLI | |
EP2700650A4 (en) | MONOCLONAL ANTIBODIES FOR THE SPECIFIC DETECTION OF HUMAN LIVER CARBOXYL ETERASE 1, HYBRIDOMA CELL LINES FOR THE MANUFACTURE OF MONOCLONAL ANTIBODIES AND USES THEREOF | |
HU0700023D0 (en) | Method for producing water-proof, heat-resistant, light construction furniture elements |